Preview

Effect of triazavirine on the outcome of a lethal influenza infection and secondary bacterial pneumonia following influenza in mice

https://doi.org/10.18527/2500-2236-2017-4-1-52-57

Полный текст:

Аннотация

Pneumonia often occurs as secondary infection post influenza disease and accounts for a large proportion of the morbidity and mortality associated with seasonal and pandemic influenza outbreaks. The antiviral drug triazavirine is licensed in Russia for the treatment and prophylaxis of acute respiratory infections, including influenza A and B viruses. In the present study, we investigated the efficacy of triazavirine in a mouse model of secondary Staphylococcus aureus pneumonia following A/California/04/2009 (H1N1)pdm09 influenza virus infection. We also performed a study of the efficacy of triazavirine against the A/California/04/2009 (H1N1)pdm09 lethal influenza infection in mice. In this model, triazavirine at the dose of 25 mg/kg/day significantly enhanced the survival of animals (60% compared to 20%) and the mean survival time to death, prevented weight loss, and reduced viral titer in the lungs of mice infected with influenza virus. At doses of 50 and 100 mg/kg/day, triazavirine was highly effective in the treatment of the secondary bacterial pneumonia following influenza infection in mice. At these doses, triazavirine protected 67-75% of animals against death, increased the mean survival time to death by twofold, and reduced the virus titer by 2.2-3.0 log10TCID50/ml compared to the mice in the control group. These findings suggest the possible benefit of triazavirine treatment in reducing post influenza pneumonia incidence in humans.

Об авторах

I. A. Leneva
Mechnikov Research Institute for Vaccines and Sera
Россия

Irina Leneva

Moscow



I. N. Falynskova
Mechnikov Research Institute for Vaccines and Sera
Россия
Moscow


N. R. Makhmudova
Mechnikov Research Institute for Vaccines and Sera
Россия
Moscow


E. A. Glubokova
Mechnikov Research Institute for Vaccines and Sera
Россия
Moscow


N. P. Kartashova
Mechnikov Research Institute for Vaccines and Sera
Россия
Moscow


E. I. Leonova
Mechnikov Research Institute for Vaccines and Sera
Россия
Moscow


N. A. Mikhailova
Mechnikov Research Institute for Vaccines and Sera
Россия
Moscow


I. V. Shestakova
Yevdokimov State University of Medicine and Dentistry
Россия
Moscow


Список литературы

1. Influenza. Bulletin of the WHO. 2014; 211. Available at: http://www.who.int/mediacentre/factsheets/fs211/ru/

2. Legand A, Briand S, Shindo N, Brooks WA, de Jong MD, Farrar J, Aguilera X., Hayden FG. Addressing the public health burden of respiratory viruses: the Battle against Respiratory Viruses (BRaVe) Initiative. Future Virology 2013, 8(10), 953-968. doi: 10.2217/fvl.13.85.

3. Potter CW. Chronicle of influenza pandemics. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of influenza. London: Blackwell Scientific Publications. 1998; 3-18.

4. Chung DR, Huh K. Novel pandemic influenza A (H1N1) and community-associated methicillinresistant Staphylococcus aureus pneumonia. Expert Rev Anti Infect Ther. 2015; 13(2), 197-207. doi: 10.1586/14787210.2015.999668.

5. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008; 198(7), 962- 70. Epub 2008/08/20. doi: 10.1086/591708.

6. Brundage JF, Shanks GD. Deaths from bacterial pneumonia during 1918-19 influenza pandemic. Emerg Infect Dis. 2008; 14(8), 1193-9. doi: 10.3201/eid1408.071313.

7. Murray RJ, Robinson JO, White JN, Hughes F, Coombs GW, Pearson JC, et al. Community-acquired pneumonia due to pandemic A(H1N1)2009 influenza virus and methicillin resistant Staphylococcus aureus co-infection. PLoS One. 2010; 5(1), e8705. doi: 10.1371/journal.pone.0008705.

8. Ortiz JR, Neuzil KM, Cooke CR, Neradilek MB, Goss CH, Shay DK. Influenza pneumonia surveillance among hospitalized adults may underestimate the burden of severe influenza disease. PLoS One. 2014; 9(11), e113903. doi: 10.1371/journal.pone.0113903.

9. Karlstrom A, Boyd KL, English BK, McCullers JA. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J Infect Dis. 2009; 199(3), 311-9. doi: 10.1086/596051.

10. Mandell L. Community acquired pneumonia. BMJ. 2010; 341, c2916. doi: 10.1136/bmj.c2916.

11. McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis. 2002; 186(3), 341-50. doi: 10.1086/341462.

12. McCullers JA. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis. 2004; 190(3), 519-26. doi: 10.1086/421525.

13. Hedlund M, Aschenbrenner LM, Jensen K, Larson JL, Fang F. Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection. J Infect Dis. 2010; 201(7):1007-15. doi: 10.1086/651170.

14. Leneva IA, Falynskova IN, Leonova EI, Fedyakina IT, Makhmudova NR, Osipova EA, et al. [Umifenovir (Arbidol) efficacy in experimental mixed viral and bacterial pneumonia of mice]. Antibiot Khimioter. 2014; 59(9-10), 17-24. PubMed PMID: 25975111.

15. Karpenko I, Deev S, Kiselev O, Charushin V, Rusinov V, Ulomsky E, et al. Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication. Antimicrob Agents Chemother. 2010; 54(5), 2017-22. doi: 10.1128/AAC.01186-09.

16. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009; 460(7258), 1021-5. doi: 10.1038/nature08260.

17. Shvetsov AV, Zabrodskaya YA, Nekrasov PA, Egorov VV. Triazavirine supramolecular complexes as modifiers of the peptide oligomeric structure. J Biomol Struct Dyn. 2017; 1-5. doi: 10.1080/07391102.2017.1367329.

18. Wu H. Higher-order assemblies in a new paradigm of signal transduction. Cell. 2013; 153(2), 287-92. doi: 10.1016/j.cell.2013.03.013.


Для цитирования:


Leneva I.A., Falynskova I.N., Makhmudova N.R., Glubokova E.A., Kartashova N.P., Leonova E.I., Mikhailova N.A., Shestakova I.V. Effect of triazavirine on the outcome of a lethal influenza infection and secondary bacterial pneumonia following influenza in mice. Microbiology Independent Research Journal (MIR Journal). 2017;4(1):52-57. https://doi.org/10.18527/2500-2236-2017-4-1-52-57

For citation:


Leneva I.A., Falynskova I.N., Makhmudova N.R., Glubokova E.A., Kartashova N.P., Leonova E.I., Mikhailova N.A., Shestakova I.V. Effect of triazavirine on the outcome of a lethal influenza infection and secondary bacterial pneumonia following influenza in mice. Microbiology Independent Research Journal (MIR Journal). 2017;4(1):52-57. https://doi.org/10.18527/2500-2236-2017-4-1-52-57

Просмотров: 30


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2500-2236 (Online)